Grade 4 thrombocytopenia with PD-1 inhibitors following progression of PD-L1 inhibitor therapy in small cell lung cancer: a case report and literature review

Abstract Immune checkpoint inhibitors (ICIs) are now a standard treatment for small cell lung cancer (SCLC). In certain cases, cross-line ICI therapy may still provide clinical benefit after disease progression; however, reports detailing the associated adverse events—particularly hematologic toxici...

Full description

Bibliographic Details

Published in:	BMC Geriatrics
Main Authors:	An Wang, Yi Dong, Dongxiao Wu, Yibing Bai, Xuhui Yang, Haitao Tao
Format:	Article
Language:	English
Published:	BMC 2025-12-01
Subjects:	Small cell lung cancer Immune checkpoint inhibitors Thrombocytopenia Durvalumab Camrelizumab Case report
Online Access:	https://doi.org/10.1186/s12877-025-06912-7